title: Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.
abstract: The understanding of the molecular mechanisms leading to peptide action entails the identification of a core active site. The major 28-aa neuropeptide, vasoactive intestinal peptide (VIP), provides neuroprotection. A lipophilic derivative with a stearyl moiety at the N-terminal and norleucine residue replacing the Met-17 was 100-fold more potent than VIP in promoting neuronal survival, acting at femtomolar-picomolar concentration. To identify the active site in VIP, over 50 related fragments containing an N-terminal stearic acid attachment and an amidated C terminus were designed, synthesized, and tested for neuroprotective properties. Stearyl-Lys-Lys-Tyr-Leu-NH2 (derived from the C terminus of VIP and the related peptide, pituitary adenylate cyclase activating peptide) captured the neurotrophic effects offered by the entire 28-aa parent lipophilic derivative and protected against beta-amyloid toxicity in vitro. Furthermore, the 4-aa lipophilic peptide recognized VIP-binding sites and enhanced choline acetyltransferase activity as well as cognitive functions in Alzheimer's disease-related in vivo models. Biodistribution studies following intranasal administration of radiolabeled peptide demonstrated intact peptide in the brain 30 min after administration. Thus, lipophilic peptide fragments offer bioavailability and stability, providing lead compounds for drug design against neurodegenerative diseases.
authors: Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel 69978, USA. igozes@post.tau.ac.il
authors: I
authors: I
authors: Gozes
authors: O
authors: O
authors: Perl
authors: E
authors: E
authors: Giladi
authors: A
authors: A
authors: Davidson
authors: O
authors: O
authors: Ashur-Fabian
authors: S
authors: S
authors: Rubinraut
authors: M
authors: M
authors: Fridkin
mesh_terms: D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000818:Animals; D000831:Animals, Newborn; D001057:Apolipoproteins E / Q000172:deficiency; D001253:Astrocytes / Q000166:cytology* / Q000187:drug effects; D001665:Binding Sites; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D015195:Drug Design; D008715:Methionine; D008969:Molecular Sequence Data; D009457:Neuroglia / Q000166:cytology* / Q000187:drug effects; D009474:Neurons / Q000166:cytology* / Q000187:drug effects; D018696:Neuroprotective Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D009646:Norleucine; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D014660:Vasoactive Intestinal Peptide / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D009842:Oligopeptides; D014660:Vasoactive Intestinal Peptide; D009646:Norleucine; D008715:Methionine; D002795:Choline O-Acetyltransferase